Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29040260 | 0.75 | PRCP (0.53) | PRCPSLC22A1GAAGID4RECQL | |
| SCHEMBL95058 | 0.75 | PRCP (0.53) | PRCPSLC22A1GAAGID4RECQL | |
| SCHEMBL1033480 | 0.75 | PRCP (0.53) | PRCPSLC22A1GAAGID4RECQL | |
| SCHEMBL29768301 | 0.71 | PRCP (0.68) | PRCPSLC22A1GAAOPRM1OPRK1 | |
| SCHEMBL16455043 | 0.71 | PRCP (0.68) | PRCPSLC22A1GAAOPRM1OPRK1 | |
| SCHEMBL1011090 | 0.71 | PRCP (0.68) | PRCPSLC22A1GAAOPRM1OPRK1 | |
| SCHEMBL10226238 | 0.71 | PRCP (0.68) | PRCPSLC22A1GAAOPRM1OPRK1 | |
| SCHEMBL1009943 | 0.69 | PRCP (0.64) | PRCPSLC22A1GAAOPRM1OPRK1 | |
| SCHEMBL24809356 | 0.69 | TSHR (0.65) | PRCPSLC22A1GAATSHRNPSR1 | |
| SCHEMBL16968355 | 0.69 | PRCP (0.59) | PRCPSLC22A1GAAOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218103-A1 | GAPDH CASCADE INHIBITOR COMPOUNDS AND METHODS OF USE AND TREATMENT OF STRESS INDUCED DISORDERS INCLUDING MENTAL ILLNESS | UNIV JOHNS HOPKINS (US) | 2015-08-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218103-A1 | GAPDH CASCADE INHIBITOR COMPOUNDS AND METHODS OF USE AND TREATMENT OF STRESS INDUCED DISORDERS INCLUDING MENTAL ILLNESS | GAPDH, CREBBP, PDK1 | PRCP 2662/4885SLC22A1 3542/4885GAA 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.